Group items matching

in title, tags, annotations or url

National Institute for Health and Care Excellence (NICE)'s diagnostic advisory committee has recommended the use of HM-JACKarc or OC-Sensor quantitative faecal immunochemical tests (FIT) in a draft guidance release for consultation on Wednesday (5 July). Under existing NICE guidance, FIT was already offered to some people presenting to primary care with symptoms suggestive of colorectal cancer, while others were immediately referred on the suspected cancer pathway. The new draft guidance will now see everyone receive a FIT. A sample is sent in the post to a laboratory where the amount of blood in the faeces is measured. The results are usually available within a week and people with 10 or more micrograms of haemoglobin in their faeces should then be referred for further investigation. Further assessment using colonoscopy, or CT colonography, is required to diagnose cancer. The tests cost between £4 and £5 per sample, and can correctly identify about 9 out of 10 people with colorectal cancer. The committee agreed it is important that GPs can refer people for colonoscopy without a positive FIT result if they think it is necessary and where symptoms persist. The institute believes that the recommendation of the tests should reduce the number of unnecessary colonoscopies, thus freeing up appointments for more non-urgent referrals. This should lead to 50% fewer referrals for urgent colonoscopies being made by GPs in primary care settings each year.

AstraZeneca said on Monday (June 27) two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company's oncology portfolio. Lynparza, a cancer drug developed jointly with U.S.-based Merck, was backed for standalone use or in combination with endocrine therapy in adults with a form of genetically mutated early-stage breast cancer. The drug, which has received a similar recommendation in the United States in March, is a key asset for AstraZeneca. It was recommended in patients with low-to-normal levels of a protein known as HER2 that is the target of several new therapies. Enhertu - developed jointly with Japan's Daiichi Sankyo (4568.T) - was the other drug that was endorsed by the European Medicines Agency for treating an aggressive form of breast cancer characterised by a high rate of HER2.

Clinical trials for BioNTech's cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company's top executive Ugur Sahin told magazine Der Spiegel. BioNTech, known for its COVID vaccine with U.S. partner Pfizer, is currently deciding which types of cancer it wants to test its personalized cancer immunotherapies on and the locations where it will conduct the trials, Sahin said. The company wants these therapies, which are based on messenger RNA (mRNA) technology similar to the one that underpins its COVID-19 vaccine, to soon become a regular treatment for cancer patients. "We believe that this should be possible for large amounts of patients before 2030," Sahin said.

NHS England has expanded its national bowel screening programme to people aged 54 so that cancers can be detected at an earlier stage when they are easier to treat. As part of the expansion, the health service would be sending a home-testing kit for bowel cancer, known as the Faecal Immunochemical Test (FIT), to thousands more people in the North West. Those who are eligible (aged 54 and over) will now automatically receive the kit every two years by post, enabling them to self-check for blood in stool samples, which can be a sign of bowel cancer. With the expansion of the NHS Bowel Cancer Screening Programme to people aged 54 years, an additional 830,000 people in England will now be eligible for the screening test.

The NHS England is rapidly expanding the targeted lung health check programme (TLHC) across England to detect lung cancers at an early stage. Launched in 2019, it is a national scheme that identifies people aged 55-74 at increased risk of lung cancer to invite them for a lung health check and chest CT scan, if appropriate. Since then, it has heled detect over 3,000 lung cancers, mostly at an early stage when the condition is more treatable, Dr Jason Page, Clinical Director of South Yorkshire and Bassetlaw targeted lung health checks, revealed in a blog on the NHS website. The decision to initiate the programme follows a study that showed CT screening reduced lung cancer mortality by 26 per cent in men and between 39 per cent and 61 per cent in women.

Of all the types of cancers that we get to see now, ovarian cancer is the most dangerous and sometimes life threatening too. Detection and treatment in the early stages goes a long way in eliminating the disease totally. Day-by-day, more women are falling prey to various types of ovarian cancers and sehat.com Gynaecologists suggest that information about the symptoms, diagnosis and treatment can help women spot the changes in their bodies and get in touch with their healthcare provider. We have listed down the ten most important things women must know about ovarian cancers. Read on and spread the information.

Hi friends ,sorry for a delayed posting.Today i'll briefly review the RISK FACTORS OF BREAST CANCER.Breast cancer is a very common cancer.Breast cancer is perhaps the most common cancer in women of the developed countries.

As suggested in the video you should contact the doctor if you find any lump in the breast or armpit, ulcer, nipple discharge, or asymmetry in both breasts. Breast cancer is most commonly present as lump however not all lumps are cancerous. Eight out of 10 lumps are not cancer.

What are the symptoms of Stomach/Gastric Cancer? Why is stomach/Gastric Cancer difficult to identify? What are the causes of Stomach/Gastric Cancer? Which factors increase the risk of Stomach/Gastric Cancer

the "Global Lung Cancer Drugs Market" will grow at a CAGR of 13.6% during the forecast period. The market has witnessed steady growth in the past few years with the introduction of novel products, which have augmented the acceptance of immunotherapy drugs in the market. The market is fueled by upsurge in the incidence of lung cancer cases across the globe - owing to increasing diagnosis rate and mainly due to increasing tobacco consumption, increase in the lung cancer treatment rates, increasing rate of effective drug approvals as first-line therapies, strategic deals to develop new products, increasing R&D spending, and rapid industrialization leading to increased pollution. The report provides complete details about the sub-segments of the lung cancer drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, and government initiatives towards the disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market.

German biotechnology company BioNTech has signed a deal with the Department of Health and Social Care to enrol up to 10,000 patients in clinical trials by the end of 2030 for personalised cancer therapies, the German drug maker said. The multi-year collaboration is focused on cancer immunotherapies based on mRNA or other drug classes, infectious disease vaccines, and investments into expanding the company's footprint in the UK, BioNTech said in a statement on Thursday (January 5). Under the agreement, the parties plan to utilise UK's clinical trial network, genomics and health data assets, aiming to enrol the first cancer patient in the second half of 2023, the company said.

Cervical screening is one of the best ways to protect women from cervical cancer, which claims nearly two lives daily in England, according to NHS England. Therefore, all women and those with a cervix between the ages of 25 and 64 are encouraged to attend cervical screening when invited. Sadly, 3 in 10 of those eligible for cervical screening do not take up the potentially life-saving offer, as revealed by the NHS Cervical Screening Programme, England 2022-2023 annual report. Pharmacist Thorrun Govind, also a Healthcare Lawyer (Brabners LLP), underscores the significant role pharmacists and pharmacy teams can play in promoting cervical cancer screening. The former Chair of the Royal Pharmaceutical Society (RPS) in England told Pharmacy Business: "Pharmacists and pharmacy teams are a trusted part of the local community. They therefore have a key part in promoting cervical cancer screening."

colon, colon cancer, colon cancer drug, colon cancer diagnosis, colon cancer treatment, chemotherapy

The cancer journal is an important and reliable source of current information on developments in the field, cancer journal research updates is a peer reviewed journals.

Today, the world is witnessing remarkable advancements in the field of anti-cancer treatment. The latest on the list is "immunotherapy". The concept of immunotherapy is based on boosting the body's own immune cells to kill or control the growth of cancer cells. Unlike chemotherapy, where chemotherapy drugs kill cancer cells, immunotherapy drugs have no direct effect on the cancer cells.

Cervical cancer vaccination is given to protect against cervical cancer. This is a cancer originating from neck of uterus- called as cervix

Cancer of the uterus, also known as uterine cancer, is a common cancer in women. This cancer can happen to any woman, but due to some reasons, the chances of getting it are high.

Aspen has committed not to charge more for its six generic cancer drugs for the next 10 years in the UK, according to the Competition and Markets Authority (CMA). The CMA also clarified that "although these commitments were offered while the UK was a part of the European Union" they remain "legally binding". It added: "The CMA has now assisted the NHS to secure binding undertakings from Aspen, under the law of England and Wales, which enshrine the UK elements of the commitments and are enforceable by UK courts, including in relation to the supply of these drugs in Northern Ireland and Scotland." This allows NHS to monitor and ensure compliance by Aspen following the UK's exit from the EU. In 2017, the European Commission began an investigation into Aspen over concerns that the company had engaged in excessive pricing for 6 off-patent cancer medicines.

GlaxoSmithKline on Wednesday (April 13) said it had agreed to buy US group Sierra Oncology, a specialist in medicines for rare forms of cancer, for $1.9 billion. The purchase, worth the equivalent of £1.6 billion, aims to support the development of new medicines alongside Sierra's bone marrow cancer treatment Momelotinib. The deal, set to be completed this year, represents a near 40-percent premium to Sierra's closing share price on Tuesday, GSK said in a statement. Momelotinib could help address the "significant unmet medical needs" of patients with the blood cancer myelofibrosis and anaemia, said GSK chief commercial officer Luke Miels. "With this proposed acquisition, we have the opportunity to potentially bring meaningful new benefits to patients and further strengthen our portfolio of specialty medicines," he added.

'Tepotinib' has been recommended by the National Institute for Health and Care Excellence (NICE) to patients with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC). The new potentially life-extending drug is available from Thursday (14 April). It has been recommended for routine use across the NHS in England through Project Orbis, a programme to review and approve promising cancer drugs helping patients access treatments faster. NICE has published its final appraisal document recommending tepotinib (also known as Tepmetko and produced by company Merck Serono Ltd) as an option for treating advanced NSCLC with METex14 skipping gene alterations in adults. People with METex14 skipping alterations of NSCLC make up between 1-2% of all adults with lung cancer in England. Tepotinib, which requires people to take two tablets once daily, provides a new targeted treatment for adults with METex14 skipping gene alterations. Just over 700 people in England would be eligible to receive tepotinib as either a first or second-line treatment.